Transcription profiling by array of ER-positive breast cancer biopsies taken before and after 4 weeks of fulvestrant treatment

ABSTRACT: Analysis of breast cancer tumors following fulvestrant treatment for 4 weeks. Fulvestrant is a highly specific ER antagonist used to treat postmenopausal women with breast cancer. Data provide insight into the molecular mechanism of action of fulvestrant on whole genome expression.

ORGANISM(S): Homo sapiens

SUBMITTER: Patani N 

PROVIDER: S-ECPF-MTAB-887 | biostudies-other | 2014 Aug

REPOSITORIES: biostudies-other